Latest from Winship

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).

Jonathon B. Cohen, MD, discusses the evolving landscape of mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma. 

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.
 

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses data presented on lung cancer during the 2018 ESMO Congress.
 

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the potential of Bruton tyrosine kinase (BTK) inhibitors in the frontline treatment of patients with mantle cell lymphoma (MCL).

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.